Results 201 to 210 of about 127,475 (345)
Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra +6 more
wiley +1 more source
This review examines the evolution of bioprinting toward minimally invasive in situ strategies for internal organ regeneration. It defines the technological roadmap from handheld systems to advanced minimally invasive bioprinting platforms, positioning soft robotics as a core enabler.
Duc Tu Vu +9 more
wiley +1 more source
Ferulic acid (FA), a naturally occurring compound, exhibits anticancer activity against 16 cancer types through multiple molecular pathways. Its enhanced delivery via nanoformulations and synergistic effects with other therapies suggest FA as a promising, food‐based adjunct for cancer symptom control until fully approved pharmaceutical options are ...
Sanzida Khatun +13 more
wiley +1 more source
Colonic Malakoplakia With an Adenomatous Appearance on Magnification Endoscopy: A Case Report. [PDF]
ABSTRACT Malakoplakia is a rare chronic granulomatous disease associated with impaired macrophage phagocytosis of bacteria. Because colonic malakoplakia presents with varied endoscopic appearances, its characteristic features have not been clearly defined, and differentiation from colorectal neoplasms during endoscopy may be difficult. We report a case
Sono S +7 more
europepmc +2 more sources
ABSTRACT Objective Immune checkpoint inhibitors (ICIs) combined with platinum‐based compounds are commonly used in the treatment of certain malignant tumors. This study aims to analyze adverse events (AEs) associated with the combination therapy of ICIs and platinum‐based compounds by using the FAERS database.
Boyi Liu +7 more
wiley +1 more source
ABSTRACT Introduction The COVID‐19 pandemic significantly disrupted colorectal cancer (CRC) diagnosis and treatment globally. Most research on long‐term impacts has focused on population‐level outcomes, overlooking disparities in under‐screened groups.
Anita Lal +7 more
wiley +1 more source

